Can Non-Thymomatous Late-Onset Myasthenia Gravis Benefit From Thymectomy? A Systematic Review and Meta-Analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/40022458/
Thymectomy may be a potentially effective treatment for LOMG, particularly in patients who undergo the procedure soon after diagnosis. A randomized controlled study for LOMG patients is needed.
Thymectomy may benefit late-onset myasthenia gravis (LOMG), especially in patients undergoing surgery soon after diagnosis. Response rates improve when MG onset is ≥45 years or thymectomy occurs at ≥50 years.
Myasthenia gravis in 2025: five new things and four hopes for the future - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39987373/
The last 10 years has brought transformative developments in the effective treatment of myasthenia gravis (MG). Beginning with the randomized trial of thymectomy in myasthenia gravis that demonstrated efficacy of...
Recent advances in myasthenia gravis treatment include thymectomy, B cell depletion, complement inhibition, and Fc receptor blockade. Future goals focus on rapid diagnosis, neuromuscular protection, aging research, and durable therapies like CAR T cells.
Tracking myasthenia gravis severity over time: Insights from the French health insurance claims database - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39494501/
A subgroup of patients with MG require ICU admission and rescue therapy with IVIg or PE, indicative of poor disease control. New therapies are needed to improve disease control and...
This study analyzed 14,459 MG patients from the French SNDS database, highlighting ICU admissions, IVIg/PE use, and mortality risks. Findings suggest poor disease control in some patients, emphasizing the need for better therapies.
Efficacy and safety of maintenance intravenous immunoglobulin in generalized myasthenia gravis patients with acetylcholine receptor antibodies: A multicenter, double-blind, placebo-controlled trial - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39506903/
Several efficacy parameters showed numerical results greater than those seen in the placebo group. This was a small study and may have been underpowered to see significant differences. Additional studies...
This randomized trial assessed IGIV-C maintenance therapy in generalized myasthenia gravis. While some efficacy measures favored IGIV-C, differences were not statistically significant. IGIV-C was well tolerated, warranting further investigation.
Myasthenia gravis complicated by pure red cell aplasia with clonal large granular lymphocytosis in the absence of thymoma: a rare case report and literature review - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39963144/
In 2013, a young woman during her early pregnancy was repeatedly hospitalized due to respiratory and swallowing difficulties. The pregnancy was terminated due to recurrent severe lung infections. She was...
A rare case of myasthenia gravis (MG) with pure red cell aplasia (PRCA) and clonal large granular cells, resolved by azathioprine cessation, highlights MG-PRCA associations without thymoma and successful pregnancy outcome.